Merus Announces Positive Phase 2 Data for Petosemtamab in mCRC
ByAinvest
Saturday, Oct 25, 2025 5:27 am ET1min read
MRUS--
Merus has announced preliminary clinical data from a phase 2 study of bispecific antibody petosemtamab in combination with standard treatment FOLFOX/FOLFIRI in first-line (1L) and second-line (2L) metastatic colorectal cancer (mCRC), as well as petosemtamab monotherapy in third-line (3L+) mCRC. The data showed a 100% response rate in 1L link-sided mCRC and a 62% response rate in 2L link- and right-sided mCRC. The study is ongoing, and updated data will be presented at the American Association for Cancer Research (AACR) annual meeting.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet